News Detail
Mumbai, 10 March 2025: In a positive development for crores of people battling diabetes in India, Empagliflozin, a crucial drug previously available at high prices, will soon be offered by domestic pharmaceutical companies at significantly lower costs. Starting March 11, the drug......
View Details
Source : News 18
mankind pharma
diabetes drug
diabetes medicine
Empagliflozin generic India
affordable diabetes treatment
Mankind Pharma Empagliflozin
diabetes drug market India
generic diabetes medications
cost-effective diabetes therapy
Boehringer Ingelheim patent expiration
Related News
- Sun Pharmaceuticals to acquire Checkpoint Therapeutics for $355 mn (10-03-2025)
- Congress MP raises issue of bogus medicines in Maha Govt hospitals in Lok Sabha (10-03-2025)
- Odisha sees surge in fake medicines; 4 suppliers blacklisted in 3 years: Dr. Mukesh Mahaling in Assembly (10-03-2025)
- CCRAS signed MoU with SNPS Jadavpur for advancing Ayurveda research in diabetes management (10-03-2025)
- Action impact against quack doctors short-lived, lasting only four days, illegal clinics have resumed operations (10-03-2025)
- Ayushman medicine scam unearthed at PGI (10-03-2025)
- NPPA to consider other sources also to fix ceiling prices of some formulations (10-03-2025)
- FDI equity inflow into pharma sector declines 12% in first nine months of FY25 (10-03-2025)
- Over 100 MSME drug firms modernizing their pharma unit as per WHO standards (10-03-2025)
- Abohar: Operator Arrested After Recovery of One Thousand Banned Capsules, No License Found (09-03-2025)